/ELAN
Elanco Animal Health Incorporated
ELAN • NYSEELAN • NYSE • Healthcare
$24.44-1.77%-0.44
$24.44-1.77%(-0.44)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
83Bullish
Risk
45Moderate
Momentum
81Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
43.5%▲0.5pp
Revenue after COGS
Operating
5.3%▼0.3pp
After operating expenses
Net
-4.9%▼12.5pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-48.4
Price vs earnings
EV/EBITDA
21.8
Enterprise value
FCF Yield
2.5%
Cash generation
Earnings Yield
-2.1%
Inverse of P/E
Capital Efficiency
-0
GoAI Quality ScorePoor
ROEReturn on Equity
-3.5%Weak
ROAReturn on Assets
-1.7%Weak
ROICReturn on Invested Capital
2.1%Fair
Financial Health
Current RatioHealthy
2.17
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
5.14x
Debt repayment capacity (<3x)
Income QualityWeak
-2.41
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.71B | $4.44B | $4.42B | $4.41B | $4.76B |
| Gross Profit | $2.05B | $1.91B | $1.94B | $1.97B | $2.08B |
| Gross Margin | 43.5% | 43.0% | 43.9% | 44.7% | 43.6% |
| Operating Income | $252.00M | $251.00M | $326.00M | $384.00M | $304.00M |
| Net Income | -$232.00M | $338.00M | -$1.23B | -$78.00M | -$483.00M |
| Net Margin | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% |
| EPS | -$0.47 | $0.68 | -$2.50 | -$0.15 | -$0.97 |
Average Price Target
$27.88▲ 14.1% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Elanco Animal Health Incorporated, the average price target is $27.88, with a high forecast of $30.00 and a low forecast of $22.00. The average price target represents a 14.1% increase from the current price of $24.44.
Highest
$30.00
Average
$27.88
Lowest
$22.00
Rating Distribution
Strong Buy
0
0%
Buy
14
70%
Hold
4
20%
Sell
2
10%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Morgan Stanley● Maintain
Equal Weight
2026-02-25Keybanc● Maintain
Overweight
2026-02-25Leerink Partners● Maintain
Outperform
2026-02-24JP Morgan● Maintain
Overweight
2026-02-19Piper Sandler▲ Upgrade
Neutral→Overweight
2026-01-22Morgan Stanley● Maintain
Equal Weight
2025-12-18UBS● Maintain
Buy
2025-11-06UBS● Maintain
Buy
2025-10-20JP Morgan▲ Upgrade
Neutral→Overweight
2025-10-07Stifel● Maintain
Buy
2025-09-24Earnings History & Surprises
BEAT RATE
83%
Last 18 quarters
AVG SURPRISE
+1.6%
EPS vs Estimate
BEATS / MISSES
15/3
Last 18 quarters
LATEST EPS
$-0.56
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-604.9%
$-0.56 vs $0.11
Q4 '25
+46.2%
$0.19 vs $0.13
Q3 '25
+30.0%
$0.26 vs $0.20
Q2 '25
+19.4%
$0.37 vs $0.31
Q1 '25
-12.5%
$0.14 vs $0.16
Q4 '24
+8.3%
$0.13 vs $0.12
Q3 '24
+25.0%
$0.30 vs $0.24
Q2 '24
+24.1%
$0.34 vs $0.27
Q1 '24
-20.0%
$0.08 vs $0.10
Q4 '23
+50.0%
$0.18 vs $0.12
Q3 '23
+260.0%
$0.18 vs $0.05
Q2 '23
+55.2%
$0.45 vs $0.29
No investor questions available.
Latest News
No news available